A partially blinded, randomized trial assessing the safety and efficacy of various doses and treatment durations of combination therapies in participants with pulmonary infection of either extensively drug-resistant tuberculosis (XDR-TB), Pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB)
Due to high patient screening and enrolment, some African sites were unable to manage kit supplies. Moreover, shipments proved challenging towards year-end and, especially, during the outbreak of the Covid-19 pandemic. The outbreak also caused strong restrictions on (international) shipping.
Discover how our team of experts rose to the occasion to help this trial succeed
Reach out to our experts and discover how we can help you advance your clinical trialContact Us